LCN2 and lung carcinoma: Collectively, the findings from studies on myeloid-specific knockout and therapy with anti-LCN2 antibody demonstrated that targeted elimination of LCN2 alleviated ferroptosis and tissue wasting significantly in mice with lung cancer cachexia.